DISCLAIMER: FOR RESEARCH USE ONLY. The material provided is "as is", and using TOPOGRAPH is without warranties of any kind, either expressed or implied. The content provided by this resource CANNOT subsitute for clinical judgement or professional oncology advice. Improper use of this resource may lead to harm.
NOTE: The haematology contents of this resource is currently under review and in the process of being updated.
Lin FP, Thavaneswaran S, Grady JP, Napier CE, Kansara M, Sebastian L, Kee D, Oakes SR, Blackburn J, Scott HS, Glover A, Fox SB, Goldstein D, Leo P, Amanuel B, Desai J, Lee CK, Ballinger ML, Simes RJ, Thomas DM. Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.J Clin Oncol 40, 2022 (suppl 16; abstr 3073). doi: 10.1200/JCO.2022.40.16_suppl.3073
The Australian Genomic Cancer Medicine Program (Omico Ltd.) acknowledges funding support from the Australian Federal Government and Office for Health and Medical Research (NSW, Australia).
FL thanks the support from the philanthropic fund of Wolf family, Prof Richard Epstein, and Kinghorn Centre for Clinical Genomics for the earlier part of this work.